Potential therapeutic effect of low-dose paclitaxel in melanoma patients resistant to immune checkpoint blockade: A pilot study
C Gebhardt, SCS Simon, R Weber, M Gries, DH Mun… - Cellular …, 2021 - Elsevier
The low dose application of chemotherapeutic agents such as paclitaxel was previously
shown to initiate anti-tumor activity by neutralizing myeloid-derived suppressor cells
(MDSCs) in melanoma mouse models. Here, we investigated immunomodulating effects of
low-dose paclitaxel in 9 metastatic melanoma patients resistant to prior treatments. Three
patients showed response to therapy (two partial responses and one stable disease). In
responding patients, paclitaxel decreased the frequency and immunosuppressive pattern of …
shown to initiate anti-tumor activity by neutralizing myeloid-derived suppressor cells
(MDSCs) in melanoma mouse models. Here, we investigated immunomodulating effects of
low-dose paclitaxel in 9 metastatic melanoma patients resistant to prior treatments. Three
patients showed response to therapy (two partial responses and one stable disease). In
responding patients, paclitaxel decreased the frequency and immunosuppressive pattern of …
